多发性硬化疾病修正治疗中MRI使用与治疗转换的相关性
该回顾性队列研究基于2018年全国去标识化理赔数据库纳入11,972例多发性硬化患者,比较2018年接受与未接受MRI者的疾病修正治疗转换情况。结果显示,在注射剂或口服疾病修正治疗患者中,影像检查中枢神经系统部位越多,转换治疗的比值越高;在接受高疗效输注治疗的患者中,MRI未改变转换治疗的比值,但仍是安全监测的必要手段。
要点
- 注射剂或口服疾病修正治疗患者中,影像部位越多,转换治疗比值越高。
- 输注高疗效治疗患者中,MRI未改变转换治疗的比值,但仍是安全监测必要手段。
- 2018年32.8%的多发性硬化患者至少接受过一次MRI检查。
核心结论
- 在注射剂或口服疾病修正治疗患者中,影像检查更多中枢神经系统部位与转换治疗比值升高相关。
- 在接受高疗效输注疾病修正治疗的患者中,MRI未改变转换治疗的比值,但仍是安全监测的必要手段。
研究设计与样本
- 回顾性队列研究,从2018年去标识化全国理赔数据库识别多发性硬化患者,样本量11,972例。
- 比较2018年接受MRI与未接受MRI的患者,观察6个月以评估疾病修正治疗转换的发生率。
- 校正年龄和复发发生率。
诊断标准与关键数值
- 总体人群MRI使用增加转换疾病修正治疗的比值:1、2、≥3个中枢神经系统部位成像的OR分别为1.49、1.79、3.01。
- 注射剂或平台疾病修正治疗患者中,任何MRI使用增加转换治疗的比值:1、2、≥3个部位成像的OR分别为1.54、2.00、3.48。
- 口服疾病修正治疗患者中,仅2个或≥3个部位MRI增加转换治疗的比值:1、2、≥3个部位的OR分别为1.36、1.89、2.40。
- 输注治疗患者中,几乎没有证据表明MRI改变转换疾病修正治疗的比值。
临床应用与阅片要点
- 在注射剂或口服疾病修正治疗患者中,影像检查中枢神经系统部位数量与治疗转换比值升高相关,阅片时可关注成像部位范围。
- 输注高疗效疾病修正治疗患者中,MRI虽未改变转换治疗比值,但仍是安全监测的必要手段。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND AND OBJECTIVES: Studies measuring the role of magnetic resonance imaging (MRI) in therapeutic decision-making are rare in people with multiple sclerosis (pwMS). This study aimed to measure the association between MRI utilization and disease-modifying therapy (DMT) switches in pwMS.
METHODS: This retrospective cohort study identified pwMS in 2018 from a de-identified national claims database. PwMS who received MRI in 2018 were compared to pwMS not receiving MRI in 2018. PwMS were observed for six months to assess the incidence of DMT switches.
RESULTS: The study sample consisted of 11,972 pwMS. 3,931 (32.8%) pwMS received at least one MRI in 2018. Overall, MRI utilization increased the odds of switching DMT (OR = 1.49, 1.79, and 3.01 for 1, 2, and ≥ 3 CNS locations imaged). For those on injectable or platform DMT, any MRI utilization increased the odds of switching DMT (OR = 1.54, 2.00, and 3.48 for 1, 2, and ≥ 3 locations imaged). For those on oral DMT, only receiving MRI of 2 or ≥ 3 locations increased the odds of a DMT switch (OR = 1.36, 1.89, and 2.40 for 1, 2, and ≥ 3 locations). Finally, for pwMS on infusible therapies, there was little evidence that MRI changed the odds of a DMT switch.
DISCUSSION: Among pwMS on injectable or oral DMT, imaging more CNS locations increased the odds of switching DMT after adjusting for age and relapse incidence. For pwMS on high-efficacy infusible DMTs, MRI did not change the odds of switching DMT but remains essential for safety monitoring.
引用
- Naizer H, Kohl Iii H, Krause T, et al. Correlation between MRI utilization and therapy switches in disease-modifying treatments for multiple sclerosis. Neuroradiology. 2024. PMID: 39395047. doi:10.1007/s00234-024-03483-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。